SlideShare a Scribd company logo
Lean authoring of Module 3
Joyce van Gerven, Regulatory Affairs Manager,
Qdossier B.V., The Netherlands
Lodewijk Venhuizen, Senior Regulatory Affairs
Manager, Crucell Switzerland AG, Switzerland
Content
©20140523 2Lean authoring of Module 3
What is Lean Authoring?
•Why Lean Authoring?
•Advantages of Lean Authoring
How to apply Lean Authoring
Lean Authoring General
Lean Authoring Module 3
Real life examples
Questions
What is Lean Authoring?
Definition of Lean Authoring
©20140523 4Lean authoring of Module 3
Split Content / Context
Naming of documents
Content of documents
Headers and footers
Content carrier
(e.g. document)
General aspects 1
Understand the difference
between documenting
information for GMP
versus regulatory dossier
• Better to give a summary of
a validation report than the
report itself that included
references to GMP
documents, like named SOPs
and internal Monographs
Separate content from
context of use
Location of
document
in dossier
or DMS
Cross references
to other content
Branding
within a
content
carrier
Context of use
Content & Context - carrot and potato recipes
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
Content & Context - every item documented
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
Content & Context – cross references
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
Content & Context – cross references
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
Content & Context - Named product in named
country for named submission type
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
If you are not the intended recipient of this disk, you
are hereby notified that any disclosure, copying,
distribution or reliance upon the contents of
this disk is strictly prohibited
eCTD on
<INN>
Sequence <…..>
Disk <x> of <n>
<Application Number>
<Type of submission>
Marketing Authorisation Number(s):
<Company logo>
Applicant:
Product Name:
Date Sent:
For technical issues contact
<………@................................>
Content & Context - Named product in named
country for named submission type
Manufacturers
Competent
authoritiesDrug
products
Production
process
(active)
substances
If you are not the intended recipient of this disk, you
are hereby notified that any disclosure, copying,
distribution or reliance upon the contents of
this disk is strictly prohibited
eCTD on
<INN>
Sequence <…..>
Disk <x> of <n>
<Application Number>
<Type of submission>
Marketing Authorisation Number(s):
<Company logo>
Applicant:
Product Name:
Date Sent:
For technical issues contact
<………@................................>
If you are not the intended recipient of this disk, you
are hereby notified that any disclosure, copying,
distribution or reliance upon the contents of
this disk is strictly prohibited
eCTD on
<INN>
Sequence <…..>
Disk <x> of <n>
<Application Number>
<Type of submission>
Marketing Authorisation Number(s):
<Company logo>
Applicant:
Product Name:
Date Sent:
For technical issues contact
<………@................................>
Lean Authoring?
©20140523 12Lean authoring of Module 3
What do we see in dossiers
• Company names and Logos
• Branding
• Same information at multiple locations
Where to improve
• Mind information that is likely to change over time
• Mind information that is likely to be different between
countries
Definition of detailed / multiple choice
• How lean should you write
Why Lean Authoring?
©20140523 13Lean authoring of Module 3
Resulting in poor:
•Retrieval of documents
•Impedes traceability
Resulting in redundant:
•Writing
•Review
•Approval
•Publishing
•Hyperlinking
•QC
Advantages of Lean Authoring
©20140523 14Lean authoring of Module 3
Document can be reused across countries
Documents can be reused across products
Improves effective communication and
review process
Improves consistency in messages
•Within and across documents
•Within and across products
•Within and across countries
Advantages of Lean Authoring
©20140523 15Lean authoring of Module 3
Eases future updates of documents
Eases future preparation of submissions
Eases retrieval of information in a document
repository and submission
Reduces the chance of rejection by
authorities
Less variations
• Manufacturer’s only described in S2.1 and P3.1
• Manufacturing process not mentioning
manufacturers
• Analytical procedures not mentioning manufacturers
How to apply Lean Authoring
What is important for dossier preparation?
©20140523 17Lean authoring of Module 3
Which marketing license to be obtained
Which claims to be supported
Which documents to be used
• Content
• Identification
• Format
• Header
• Cross references
How to communicate?
• Verbally
• Written
• eMail
• Meeting minutes
• Project plans
• Document management systems (trackability, traceability)
©20140523 Lean authoring of Module 3 18
from Qdossier
©20140523 Lean authoring of Module 3 19
from Qdossier
©20140523 Lean authoring of Module 3 20
Dossier Plan Lifecycle
Lean Authoring
Lean Authoring
©20140523 22Lean authoring of Module 3
Provide information only once in a dossier
 only in one document
Provide it at the correct (or most
appropriate) location
Be concise
Use the same terms; prevent use of
synonyms
Refer to the data provided elsewhere
rather than repeat
Lean Authoring – Rules
Consistency
©20140523 23Lean authoring of Module 3
All information in the dossier needs to be
consistent
•The less repetition, the smaller the risk for
inconsistencies
Re-use documents across products to
•Reduce the risk of inconsistencies and
compliance issues
•Increase the possibility for grouping and work
sharing across products (only EU)
Lean authoring – Rules
Cross references
©20140523 24Lean authoring of Module 3
Cross-references to other products in time
independent documents to justify the
quality, safety or efficacy.
• Not advisable, don’t do it
• It puts your product at risk when something unforeseen
happens to the referenced product
Lean authoring – General
©20140523 25Lean authoring of Module 3
Apply default Word numbering:
• 4.4 Lyophilisation and stabilisation
Instead of
3.2.S.2.2.4.4 Lyophilisation and stabilisation
• Figure 1 Manufacturing process flow diagram
Instead of
Figure 3.2.S.2.2-1 Manufacturing process flow diagram
• Apply default Word References
• Tables and figures references in text using cross-references
Lean authoring – Text
©20140523 26Lean authoring of Module 3
Words that should be avoided:
• In order
• Assume
• New/Old
• Possibly
• Please
What else should be avoided
• Long sentences
• Sentences starting with
• With this variation/submission …
• …we (the company) shows
• We (the company) would like to …
Lean authoring Module 3
Real life examples
Pro
Easy to navigate
when using eCTD
.xml or NeeS ToC
Only small document
to revise for variation
Better reusability of
documents between
products
Con
Difficult to navigate
when using Windows
Explorer
Large document to
revise for variation 
all content might be
reviewed again
©20140523 Lean authoring of Module 3 28
Pros and cons of high document granularity
Granularity and appearance of documents
©20140523 29Lean authoring of Module 3
Per document
•Corresponding to the content plan
One doc per section 
Multiple docs per section 
Single vs. Multiple Granularity
©20140523 30Lean authoring of Module 3
3.2.P.8.1 Stability Summary and Conclusion
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed
diam nonummy nibh euismod tincidunt ut laoreet dolore magna
aliquam erat volutpat. Ut wisi enim ad minim veniam, quis
nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip
ex ea commodo consequat. Duis autem vel eum iriure dolor in
hendrerit in vulputate velit esse molestie consequat, vel illum
dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto
odio dignissim qui
3.2.P.8.2 Post-Approval Stability Protocol and Stability
Commitment
Nam liber tempor cum soluta nobis eleifend option congue nihil
imperdiet doming id quod mazim placerat facer possim assum.
Typi non habent claritatem insitam; est usus legentis in iis qui
facit eorum claritatem. Investigationes demonstraverunt lectores
legere me lius quod ii legunt saepius. Claritas est etiam processus
dynamicus, qui sequitur mutationem consuetudium lectorum.
Mirum est notare quam littera gothica, quam nunc putamus
parum claram, anteposuerit litterarum formas humanitatis per
seacula quarta decima et quinta decima. Eodem modo typi, qui
nunc nobis videntur parum clari, fiant sollemnes in futurum.
3.2.P.8.3 Stability Data
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed
diam nonummy nibh euismod tincidunt ut laoreet dolore magna
aliquam erat volutpat. Ut wisi enim ad minim veniam, quis
nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip
ex ea commodo consequat. Duis autem vel eum iriure
Lorem ipsum dolor sit amet, consectetuer adipiscing
elit, sed diam nonummy nibh euismod tincidunt ut
laoreet dolore magna aliquam erat volutpat. Ut wisi
enim ad minim veniam, quis nostrud exerci tation
ullamcorper suscipit lobortis nisl ut aliquip ex ea
commodo consequat. Duis autem vel eum iriure dolor in
hendrerit in vulputate velit esse molestie consequat, vel
illum dolore eu feugiat nulla facilisis at vero eros et
accumsan et iusto odio dignissim qui
Nam liber tempor cum soluta nobis eleifend option congue
nihil imperdiet doming id quod mazim placerat facer
possim assum. Typi non habent claritatem insitam; est usus
legentis in iis qui facit eorum claritatem. Investigationes
demonstraverunt lectores legere me lius quod ii legunt
saepius. Claritas est etiam processus dynamicus, qui
sequitur mutationem consuetudium lectorum. Mirum est
notare quam littera gothica, quam nunc putamus parum
claram, anteposuerit litterarum formas humanitatis per
seacula quarta decima et quinta decima. Eodem modo
Lorem ipsum dolor sit amet, consectetuer adipiscing
elit, sed diam nonummy nibh euismod tincidunt ut
laoreet dolore magna aliquam erat volutpat. Ut wisi
enim ad minim veniam, quis nostrud exerci tation
ullamcorper suscipit lobortis nisl ut aliquip ex ea
commodo consequat. Duis autem vel eum iriure
Appearance of documents
©20140523 31Lean authoring of Module 3
Document-specific headers, so:
•NOT Uniform across a dossier!
•NOT Referencing the dossier!
Appearance of documents
©20140523 32Lean authoring of Module 3
Not this
But this
Appearance of documents
©20140523 33Lean authoring of Module 3
Proper styles
•Heading numbering not including CTD section #
•Table/figure numbering not including section #
©20140523 Lean authoring of Module 3 34
Lifecycle example
0000
Pilot Scale
Initial stability
0001
Pilot Scale
Extension stability
Long-term 12 M
stability data
0010
Commercial scale
Initial stability
0011
Commercial Scale
Extension stability
Long-term 24 M
stability data
Current
View
Long-term 12 M
stability data
Long-term 24 M
stability data
Long-term 12 M
stability data
commercial scale
Long-term 12 M
stability data
commercial scale
Long-term 24 M
stability data
commercial scale
Long-term 24 M
stability data
commercial scale
Short-term
stability data
Short-term
stability data
Short-term
stability data
commercial scale
Short-term
stability data
commercial scale
Collaboration
Crucell and Qdossier
©20140523 36Lean authoring of Module 3
Set up of new dossier for influenza vaccine
Inherited dossier Baseline dossier (to go)
No strict separation DS/DP Defined the DS and DP
Usage of (translated) SOPs Summaries and general description
Local documents No local documents, but summaries
Usage of Brandname throughout dossier Use generic name
Inconsistent naming Naming convention introduced (DS; DP)
Master files/ full dossiers suppliers Make list of important parameters (summary)
Long text Shorter text, summaries, translations
QOS QOS rewritten
What could Qdossier do?
©20140523 37Lean authoring of Module 3
Place the information at the correct dossier section
• Crucell and Qdossier understanding of the content
• Repetition of information in DS and DP
Summarise lengthy dossier sections (content)
• Creation of new (e)CTD documents
• Ease the upload into the company’s ‘documentation’ system
Overview of all Documents
• Important having the overview of documents from the old dossier to
the new dossier
• Creation of the Content Plan (ToC, etc)
CRO’s and Client’s agreements
©20140523 38Lean authoring of Module 3
Delivery of a clear source data package
Good agreements in who is doing what
Goal setting
Manage the internal teams for review of
the documents
Knowledge of the content
•Check that nothing is missing
•No changes introduced, even minor
Challenges and solutions
©20140523 39Lean authoring of Module 3
Understanding of the content for Q-Dossier
•Questions on content
•New definitions
Tracker of the questions and answers
•GAP analysis
Meetings
•Kick off
•Life meetings (F2F)
•Weekly TC
Questions ?
Rolling out at Crucell
©20140523 41Lean authoring of Module 3
Experience with HA
• Documents used for submission
• Feedback HA
Next steps other vaccines Crucell
• Project started on lean and eCTD
• Experience will be used
Questions?

More Related Content

Similar to Lean authoring of module 3

Phase Two: What’s Next for Life Sciences and Enterprise Content Management
Phase Two: What’s Next for Life Sciences and Enterprise Content ManagementPhase Two: What’s Next for Life Sciences and Enterprise Content Management
Phase Two: What’s Next for Life Sciences and Enterprise Content ManagementScott Abel
 
The objectives of this chapter are to describe the different types of documen...
The objectives of this chapter are to describe the different types of documen...The objectives of this chapter are to describe the different types of documen...
The objectives of this chapter are to describe the different types of documen...MohamedIFADA
 
Ch3-Software Engineering 9
Ch3-Software Engineering 9Ch3-Software Engineering 9
Ch3-Software Engineering 9Ian Sommerville
 
Володимир Довганик “5 typical features that make BA mad”
Володимир Довганик “5 typical features that make BA mad”Володимир Довганик “5 typical features that make BA mad”
Володимир Довганик “5 typical features that make BA mad”Dakiry
 
Agile software development and challenges
Agile software development and challengesAgile software development and challenges
Agile software development and challengeseSAT Publishing House
 
Agile Method - Lec 1-2-3
Agile Method - Lec 1-2-3Agile Method - Lec 1-2-3
Agile Method - Lec 1-2-3Ahmed Alageed
 
Agile software development and challenges
Agile software development and challengesAgile software development and challenges
Agile software development and challengeseSAT Journals
 
Roadmap planning approach
Roadmap planning approachRoadmap planning approach
Roadmap planning approachRobert Mobley
 
Software Engineering Methodologies
Software Engineering MethodologiesSoftware Engineering Methodologies
Software Engineering MethodologiesNesrine Shokry
 
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...Decision CAMP
 
Document Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automateDocument Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automateJeff Thomas
 
Chapter 3 software engineering.pptx
Chapter 3 software engineering.pptxChapter 3 software engineering.pptx
Chapter 3 software engineering.pptx02LabiqaIslam
 

Similar to Lean authoring of module 3 (20)

agile.ppt
agile.pptagile.ppt
agile.ppt
 
Scrun Safe Ppt.pptx
Scrun Safe Ppt.pptxScrun Safe Ppt.pptx
Scrun Safe Ppt.pptx
 
Agile
AgileAgile
Agile
 
agile.ppt
agile.pptagile.ppt
agile.ppt
 
Phase Two: What’s Next for Life Sciences and Enterprise Content Management
Phase Two: What’s Next for Life Sciences and Enterprise Content ManagementPhase Two: What’s Next for Life Sciences and Enterprise Content Management
Phase Two: What’s Next for Life Sciences and Enterprise Content Management
 
The objectives of this chapter are to describe the different types of documen...
The objectives of this chapter are to describe the different types of documen...The objectives of this chapter are to describe the different types of documen...
The objectives of this chapter are to describe the different types of documen...
 
Know the user
Know the userKnow the user
Know the user
 
Documentation Checklist
Documentation ChecklistDocumentation Checklist
Documentation Checklist
 
Ch3-Software Engineering 9
Ch3-Software Engineering 9Ch3-Software Engineering 9
Ch3-Software Engineering 9
 
Володимир Довганик “5 typical features that make BA mad”
Володимир Довганик “5 typical features that make BA mad”Володимир Довганик “5 typical features that make BA mad”
Володимир Довганик “5 typical features that make BA mad”
 
Agile software development and challenges
Agile software development and challengesAgile software development and challenges
Agile software development and challenges
 
Ch3
Ch3Ch3
Ch3
 
Agile Method - Lec 1-2-3
Agile Method - Lec 1-2-3Agile Method - Lec 1-2-3
Agile Method - Lec 1-2-3
 
Agile software development and challenges
Agile software development and challengesAgile software development and challenges
Agile software development and challenges
 
Roadmap planning approach
Roadmap planning approachRoadmap planning approach
Roadmap planning approach
 
Software Engineering Methodologies
Software Engineering MethodologiesSoftware Engineering Methodologies
Software Engineering Methodologies
 
Agile process
Agile processAgile process
Agile process
 
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...
Decision CAMP 2014 - Benjamin Grosof Janine Bloomfield - Explanation-based E-...
 
Document Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automateDocument Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automate
 
Chapter 3 software engineering.pptx
Chapter 3 software engineering.pptxChapter 3 software engineering.pptx
Chapter 3 software engineering.pptx
 

Recently uploaded

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Catherine Liao
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...kevinkariuki227
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...kevinkariuki227
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAkashGanganePatil1
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsShweta
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSavita Shen $i11
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxgauripg8
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdfKs doctor
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawahpal078100
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...KavyasriPuttamreddy
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentabdeli bhadarva
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...Catherine Liao
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgeryKafrELShiekh University
 

Recently uploaded (20)

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 

Lean authoring of module 3

  • 1. Lean authoring of Module 3 Joyce van Gerven, Regulatory Affairs Manager, Qdossier B.V., The Netherlands Lodewijk Venhuizen, Senior Regulatory Affairs Manager, Crucell Switzerland AG, Switzerland
  • 2. Content ©20140523 2Lean authoring of Module 3 What is Lean Authoring? •Why Lean Authoring? •Advantages of Lean Authoring How to apply Lean Authoring Lean Authoring General Lean Authoring Module 3 Real life examples Questions
  • 3. What is Lean Authoring?
  • 4. Definition of Lean Authoring ©20140523 4Lean authoring of Module 3 Split Content / Context Naming of documents Content of documents Headers and footers
  • 5. Content carrier (e.g. document) General aspects 1 Understand the difference between documenting information for GMP versus regulatory dossier • Better to give a summary of a validation report than the report itself that included references to GMP documents, like named SOPs and internal Monographs Separate content from context of use Location of document in dossier or DMS Cross references to other content Branding within a content carrier Context of use
  • 6. Content & Context - carrot and potato recipes Manufacturers Competent authoritiesDrug products Production process (active) substances
  • 7. Content & Context - every item documented Manufacturers Competent authoritiesDrug products Production process (active) substances
  • 8. Content & Context – cross references Manufacturers Competent authoritiesDrug products Production process (active) substances
  • 9. Content & Context – cross references Manufacturers Competent authoritiesDrug products Production process (active) substances
  • 10. Content & Context - Named product in named country for named submission type Manufacturers Competent authoritiesDrug products Production process (active) substances If you are not the intended recipient of this disk, you are hereby notified that any disclosure, copying, distribution or reliance upon the contents of this disk is strictly prohibited eCTD on <INN> Sequence <…..> Disk <x> of <n> <Application Number> <Type of submission> Marketing Authorisation Number(s): <Company logo> Applicant: Product Name: Date Sent: For technical issues contact <………@................................>
  • 11. Content & Context - Named product in named country for named submission type Manufacturers Competent authoritiesDrug products Production process (active) substances If you are not the intended recipient of this disk, you are hereby notified that any disclosure, copying, distribution or reliance upon the contents of this disk is strictly prohibited eCTD on <INN> Sequence <…..> Disk <x> of <n> <Application Number> <Type of submission> Marketing Authorisation Number(s): <Company logo> Applicant: Product Name: Date Sent: For technical issues contact <………@................................> If you are not the intended recipient of this disk, you are hereby notified that any disclosure, copying, distribution or reliance upon the contents of this disk is strictly prohibited eCTD on <INN> Sequence <…..> Disk <x> of <n> <Application Number> <Type of submission> Marketing Authorisation Number(s): <Company logo> Applicant: Product Name: Date Sent: For technical issues contact <………@................................>
  • 12. Lean Authoring? ©20140523 12Lean authoring of Module 3 What do we see in dossiers • Company names and Logos • Branding • Same information at multiple locations Where to improve • Mind information that is likely to change over time • Mind information that is likely to be different between countries Definition of detailed / multiple choice • How lean should you write
  • 13. Why Lean Authoring? ©20140523 13Lean authoring of Module 3 Resulting in poor: •Retrieval of documents •Impedes traceability Resulting in redundant: •Writing •Review •Approval •Publishing •Hyperlinking •QC
  • 14. Advantages of Lean Authoring ©20140523 14Lean authoring of Module 3 Document can be reused across countries Documents can be reused across products Improves effective communication and review process Improves consistency in messages •Within and across documents •Within and across products •Within and across countries
  • 15. Advantages of Lean Authoring ©20140523 15Lean authoring of Module 3 Eases future updates of documents Eases future preparation of submissions Eases retrieval of information in a document repository and submission Reduces the chance of rejection by authorities Less variations • Manufacturer’s only described in S2.1 and P3.1 • Manufacturing process not mentioning manufacturers • Analytical procedures not mentioning manufacturers
  • 16. How to apply Lean Authoring
  • 17. What is important for dossier preparation? ©20140523 17Lean authoring of Module 3 Which marketing license to be obtained Which claims to be supported Which documents to be used • Content • Identification • Format • Header • Cross references How to communicate? • Verbally • Written • eMail • Meeting minutes • Project plans • Document management systems (trackability, traceability)
  • 18. ©20140523 Lean authoring of Module 3 18 from Qdossier
  • 19. ©20140523 Lean authoring of Module 3 19 from Qdossier
  • 20. ©20140523 Lean authoring of Module 3 20 Dossier Plan Lifecycle
  • 22. Lean Authoring ©20140523 22Lean authoring of Module 3 Provide information only once in a dossier  only in one document Provide it at the correct (or most appropriate) location Be concise Use the same terms; prevent use of synonyms Refer to the data provided elsewhere rather than repeat
  • 23. Lean Authoring – Rules Consistency ©20140523 23Lean authoring of Module 3 All information in the dossier needs to be consistent •The less repetition, the smaller the risk for inconsistencies Re-use documents across products to •Reduce the risk of inconsistencies and compliance issues •Increase the possibility for grouping and work sharing across products (only EU)
  • 24. Lean authoring – Rules Cross references ©20140523 24Lean authoring of Module 3 Cross-references to other products in time independent documents to justify the quality, safety or efficacy. • Not advisable, don’t do it • It puts your product at risk when something unforeseen happens to the referenced product
  • 25. Lean authoring – General ©20140523 25Lean authoring of Module 3 Apply default Word numbering: • 4.4 Lyophilisation and stabilisation Instead of 3.2.S.2.2.4.4 Lyophilisation and stabilisation • Figure 1 Manufacturing process flow diagram Instead of Figure 3.2.S.2.2-1 Manufacturing process flow diagram • Apply default Word References • Tables and figures references in text using cross-references
  • 26. Lean authoring – Text ©20140523 26Lean authoring of Module 3 Words that should be avoided: • In order • Assume • New/Old • Possibly • Please What else should be avoided • Long sentences • Sentences starting with • With this variation/submission … • …we (the company) shows • We (the company) would like to …
  • 27. Lean authoring Module 3 Real life examples
  • 28. Pro Easy to navigate when using eCTD .xml or NeeS ToC Only small document to revise for variation Better reusability of documents between products Con Difficult to navigate when using Windows Explorer Large document to revise for variation  all content might be reviewed again ©20140523 Lean authoring of Module 3 28 Pros and cons of high document granularity
  • 29. Granularity and appearance of documents ©20140523 29Lean authoring of Module 3 Per document •Corresponding to the content plan One doc per section  Multiple docs per section 
  • 30. Single vs. Multiple Granularity ©20140523 30Lean authoring of Module 3 3.2.P.8.1 Stability Summary and Conclusion Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui 3.2.P.8.2 Post-Approval Stability Protocol and Stability Commitment Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum. Typi non habent claritatem insitam; est usus legentis in iis qui facit eorum claritatem. Investigationes demonstraverunt lectores legere me lius quod ii legunt saepius. Claritas est etiam processus dynamicus, qui sequitur mutationem consuetudium lectorum. Mirum est notare quam littera gothica, quam nunc putamus parum claram, anteposuerit litterarum formas humanitatis per seacula quarta decima et quinta decima. Eodem modo typi, qui nunc nobis videntur parum clari, fiant sollemnes in futurum. 3.2.P.8.3 Stability Data Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum. Typi non habent claritatem insitam; est usus legentis in iis qui facit eorum claritatem. Investigationes demonstraverunt lectores legere me lius quod ii legunt saepius. Claritas est etiam processus dynamicus, qui sequitur mutationem consuetudium lectorum. Mirum est notare quam littera gothica, quam nunc putamus parum claram, anteposuerit litterarum formas humanitatis per seacula quarta decima et quinta decima. Eodem modo Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure
  • 31. Appearance of documents ©20140523 31Lean authoring of Module 3 Document-specific headers, so: •NOT Uniform across a dossier! •NOT Referencing the dossier!
  • 32. Appearance of documents ©20140523 32Lean authoring of Module 3 Not this But this
  • 33. Appearance of documents ©20140523 33Lean authoring of Module 3 Proper styles •Heading numbering not including CTD section # •Table/figure numbering not including section #
  • 34. ©20140523 Lean authoring of Module 3 34 Lifecycle example 0000 Pilot Scale Initial stability 0001 Pilot Scale Extension stability Long-term 12 M stability data 0010 Commercial scale Initial stability 0011 Commercial Scale Extension stability Long-term 24 M stability data Current View Long-term 12 M stability data Long-term 24 M stability data Long-term 12 M stability data commercial scale Long-term 12 M stability data commercial scale Long-term 24 M stability data commercial scale Long-term 24 M stability data commercial scale Short-term stability data Short-term stability data Short-term stability data commercial scale Short-term stability data commercial scale
  • 36. ©20140523 36Lean authoring of Module 3 Set up of new dossier for influenza vaccine Inherited dossier Baseline dossier (to go) No strict separation DS/DP Defined the DS and DP Usage of (translated) SOPs Summaries and general description Local documents No local documents, but summaries Usage of Brandname throughout dossier Use generic name Inconsistent naming Naming convention introduced (DS; DP) Master files/ full dossiers suppliers Make list of important parameters (summary) Long text Shorter text, summaries, translations QOS QOS rewritten
  • 37. What could Qdossier do? ©20140523 37Lean authoring of Module 3 Place the information at the correct dossier section • Crucell and Qdossier understanding of the content • Repetition of information in DS and DP Summarise lengthy dossier sections (content) • Creation of new (e)CTD documents • Ease the upload into the company’s ‘documentation’ system Overview of all Documents • Important having the overview of documents from the old dossier to the new dossier • Creation of the Content Plan (ToC, etc)
  • 38. CRO’s and Client’s agreements ©20140523 38Lean authoring of Module 3 Delivery of a clear source data package Good agreements in who is doing what Goal setting Manage the internal teams for review of the documents Knowledge of the content •Check that nothing is missing •No changes introduced, even minor
  • 39. Challenges and solutions ©20140523 39Lean authoring of Module 3 Understanding of the content for Q-Dossier •Questions on content •New definitions Tracker of the questions and answers •GAP analysis Meetings •Kick off •Life meetings (F2F) •Weekly TC
  • 41. Rolling out at Crucell ©20140523 41Lean authoring of Module 3 Experience with HA • Documents used for submission • Feedback HA Next steps other vaccines Crucell • Project started on lean and eCTD • Experience will be used

Editor's Notes

  1. It is very important to understand that a regulatory dossier is reviewed to obtain a marketing license per product, while the manufacturers are inspected for GMP compliance. Therefore do not mix up regulatory documentation with GMP documentation. Be careful with including references to named GMP documents. Better to indicate that a topic is subject to GMP and therefore covered by valid GMP certificates. If SOPs have to be submitted as part of a Method validation package, it is not subject to regulatory review, but required to repeat the tests by the agency. As a result, these documents are to be located in 32R and not in 32S or 32P. It is also better to create separate regulatory documents for analytical procedures rather than submitting the GMP-documents.
  2. Content plan: refer to earlier session of the conference
  3. This looks like to have a link to variations ... why is this for lean authoring?
  4. 20130226
  5. New documents will be created, therefore you don't want to miss information. Some information will be moved to other parts.
  6. Joyce will have a question: What I was wondering … after the project what have you done with the experience and what we have provided?
  7. Tell about the experience of our submission to AIFA on the dossier for Adimmune intro-inflexal V Epaxal started project to introduce eCTD with Q-Dossier; Usage of templates, lean writing will be introduced for next projects …